Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

4.547 -0.173 (-3.66%)
Delayed Quote Updated: 1:08 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing... 
Via TheNewswire.com
News headline image
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
News headline image
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasdaq:... 
Via TheNewswire.com
News headline image
Neurothera Labs Inc. Announces Share Consolidation
Toronto, Ontario – August 28, 2026 –– TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC),... 
Via TheNewswire.com
News headline image
NeuroThera Labs Engages Dr. Reuter Investor Relations
Toronto, Ontario – August 27, 2026 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC),... 
Via TheNewswire.com
News headline image
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
From SciSparc Ltd
Via GlobeNewswire
News headline image
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.
Toronto, Ontario – June 3, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the “Company” or “NeuroThera”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd.... 
Via TheNewswire.com
Topics Intellectual Property
News headline image
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc Announces 1-for-9 Reverse Share Split
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.